Aspire BioPharma, Inc. (ASBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has a cash flow conversion efficiency ratio of -0.785x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.04 Million) by net assets ($3.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aspire BioPharma, Inc. net asset quality index to measure how much of total assets are equity-financed.
Aspire BioPharma, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Aspire BioPharma, Inc. to evaluate the quality of earnings relative to operating cash generation.
Aspire BioPharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aspire BioPharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baijiayun Group Ltd
NASDAQ:RTC
|
-1.214x |
|
Xcel Brands Inc
NASDAQ:XELB
|
-0.067x |
|
BSL Corp Bhd
KLSE:7221
|
0.024x |
|
Cambridge Technology Enterprises Limited
NSE:CTE
|
0.319x |
|
SCC Holdings Bhd
KLSE:0158
|
0.075x |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
-0.028x |
|
Bonk, Inc.
NASDAQ:BNKK
|
-0.058x |
|
Asuransi Bina Dana Arta Tbk
JK:ABDA
|
0.018x |
Annual Cash Flow Conversion Efficiency for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Aspire BioPharma, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.38 Million | $-4.92 Million | 0.772x | +348.43% |
| 2024-12-31 | $-1.54 Million | $-265.19K | 0.172x | +616.19% |
| 2023-12-31 | $19.58 Million | $-653.11K | -0.033x | -584.45% |
| 2022-12-31 | $289.07 Million | $-1.41 Million | -0.005x | -100.89% |
| 2021-12-31 | $-475.00 | $-260.00 | 0.547x | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more